Given the pleiotropic metabolic benefits elicited by Nrg4, biologic therapeutics targeting this pathway may provide an effective treatment that simultaneously targets type 2 diabetes and NAFLD in patients. This evidence concerns the gene NRG4 and metabolic dysfunction-associated steatotic liver disease.